Histopathological risk factors for malignancy in dermatomyositis.
CD123+ plasmacytoid dendritic cells
basement membrane thickening
dermatomyositis
eosinophils
histopathological risk factors
malignant neoplasms
pigment incontinence
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
12
07
2022
received:
16
05
2022
accepted:
15
07
2022
pubmed:
26
7
2022
medline:
14
9
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
To identify possible histopathological risk factors for malignancy in skin biopsies of dermatomyositis patients. We analysed clinical metadata and studied 30 skin biopsies of 11 patients with and 12 patients without associated malignancy, who were treated in one secondary and one tertiary German medical centre between 2009 and 2022 and fulfilling the EULAR/ACR classification criteria for dermatomyositis. Specimens were categorized by malignancy status and evaluated based on haematoxylin and eosin (H&E), periodic acid Schiff (PAS), Alcian Blue, and anti-CD123 immunohistochemistry stains. After correcting for multiple testing, biopsies of patients with cancer exhibited more severe basement membrane thickening (P < 0.05) and pigment incontinence (P < 0.05) compared to patients without tumour burden. Patients with numerous subepidermal melanophages had a more than 5-times increased odds ratio to suffer from an internal malignancy (odds ratio [OR] 5.3, 95% confidence interval [CI] 1.3-54.2, P < 0.05). Furthermore, specimens of the malignancy group presented a distinct superficial distribution pattern of CD123+ plasmacytoid dendritic cells (PDCs, P < 0.01). Extravascular eosinophils were absent in all cases. Severity of basement membrane thickening, extent of pigment incontinence, and superficial distribution pattern of CD123+ PDCs could serve as useful histopathological indicators of risk for malignancy in dermatomyositis.
Substances chimiques
Interleukin-3 Receptor alpha Subunit
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-535Informations de copyright
© 2022 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J. Am. Acad. Dermatol. 2020; 82; 267-281. https://doi.org/10.1016/j.jaad.2019.06.1309.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 1975; 292; 344-347. https://doi.org/10.1056/NEJM197502132920706.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 1975; 292; 403-407. https://doi.org/10.1056/NEJM197502202920807.
Fardet L, Dupuy A, Gain M et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine 2009; 88; 91-97. https://doi.org/10.1097/MD.0b013e31819da352.
Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N. Engl. J. Med. 1992; 326; 363-367. https://doi.org/10.1056/NEJM199202063260602.
Zahr ZA, Baer AN. Malignancy in myositis. Curr. Rheumatol. Rep. 2011; 13; 208-215. https://doi.org/10.1007/s11926-011-0169-7.
Limaye V, Luke C, Tucker G et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol. Int. 2013; 33; 965-971. https://doi.org/10.1007/s00296-012-2489-y.
Lauinger J, Ghoreschi K, Volc S. Characteristics of dermatomyositis patients with and without associated malignancy. J. Dtsch. Dermatol. Ges. 2021; 19; 1601-1611. https://doi.org/10.1111/ddg.14566.
Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front. Immunol. 2017; 8; 992. https://doi.org/10.3389/fimmu.2017.00992.
Fang Y-F, Wu Y-JJ, Kuo C-F, Luo S-F, Yu K-H. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin. Rheumatol. 2016; 35; 1977-1984. https://doi.org/10.1007/s10067-016-3296-8.
Lu X, Yang H, Shu X et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 2014; 9; e94128. https://doi.org/10.1371/journal.pone.0094128.
Ackerman AB. Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis. 2nd ed. Baltimore: Williams & Wilkins, 1997.
LeBoit PE. Interface dermatitis. How specific are its histopathologic features? Arch. Dermatol. 1993; 129; 1324-1328. https://doi.org/10.1001/archderm.129.10.1324.
Sharon VR, Konia TH, Barr KL, Fung MA. Assessment of the 'no eosinophils' rule: are eosinophils truly absent in pityriasis lichenoides, connective tissue disease, and graft-vs.-host disease? J. Cutan. Pathol. 2012; 39; 413-418. https://doi.org/10.1111/j.1600-0560.2012.01891.x.
McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J. Cutan. Pathol. 2008; 35; 452-456. https://doi.org/10.1111/j.1600-0560.2007.00848.x.
Wollenberg A, Wagner M, Günther S et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol. 2002; 119; 1096-1102. https://doi.org/10.1046/j.1523-1747.2002.19515.x.
R Core Team. R: A language and environment for statistical computing. 2021. Available at: https://www.r-project.org/
Calonje E, Brenn T, Lazar A, Billings SD. McKee's pathology of the skin: With clinical correlations / [edited by] Eduardo Calonje MD, DipRCPath, Thomas Brenn MD, PhD, FRCPath, Alexander J. Lazar MD, PhD and Steven D. Billings MD. Fifth ed. Edinburgh, Scotland: Elsevier, 2020.
Wolstencroft PW, Rieger KE, Leatham HW, Fiorentino DF. Clinical factors associated with cutaneous histopathologic findings in dermatomyositis. J. Cutan. Pathol. 2019; 46; 401-410. https://doi.org/10.1111/cup.13442.
Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tüting T. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin. Exp. Dermatol. 2006; 31; 576-582. https://doi.org/10.1111/j.1365-2230.2006.02150.x.
Jasso-Olivares J, Diaz-Gonzalez JM, Miteva M. Horizontal and vertical sections of scalp biopsy specimens from dermatomyositis patients with scalp involvement. J. Am. Acad. Dermatol. 2018; 78; 1178-1184. https://doi.org/10.1016/j.jaad.2018.01.031.
Khanna U, Vaughan H, North J, Haemel A. Quantitative assessment of eosinophils in dermatomyositis skin biopsies with correlation of eosinophils to pruritus and other clinical features. Am. J. Dermatopathol. 2021; 43; 287-290. https://doi.org/10.1097/DAD.0000000000001765.
Hunger RE, Dürr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 2001; 202; 123-126. https://doi.org/10.1159/000051611.
Shakshouk H, Deschaine MA, Wetter DA et al. Do histopathological features correlate with systemic manifestations in dermatomyositis? Analysis of 42 skin biopsy specimens from 22 patients. J. Cutan. Pathol. 2022; 49; 442-447. https://doi.org/10.1111/cup.14203.